Oruka Therapeutics (ORKA) CMO Joana Goncalves Exercises Options, Sells Shares

What Happened Joana Goncalves, Chief Medical Officer of Oruka Therapeutics (ORKA), reported same‑day option exercises and multiple share sales on September 15, 2026. She exercised two option tranches for 3,500 shares each (7,000 shares total) at $6.84 and $7.80, costing $23,940 and $27,300 respectively (total exercise cost $51,240). Separately, she disposed of 7,947 shares in open‑market sales at weighted average prices, generating aggregate proceeds of approximately $734,145. The filing also shows two derivative disposals of 3,500 shares each reported at $0.00 (reported as derivative dispositions).

Key Details

• Transaction date: September 15, 2026.
• Exercises (code M): 3,500 shares @ $6.84 ($23,940) and 3,500 shares @ $7.80 ($27,300) — total 7,000 shares acquired via exercise.
• Sales (code S): 2,384 shares @ $91.10; 3,150 shares @ $92.03; 1,366 shares @ $92.99; 100 shares @ $94.22; 947 shares @ $95.71 — total sold = 7,947 shares; total proceeds ≈ $734,145.
• Two derivative dispositions reported at $0.00 for 3,500 shares each (listed as derivative transactions).
• Footnotes of note:
  • F1: The sales were effected under a Rule 10b5‑1 trading plan (entered Sept 19, 2025).
  • F2–F5: Reported sale prices are weighted averages; individual trade price ranges are provided in the filing.
  • F6: Company automatic sell‑to‑cover used for tax withholding (for restricted stock unit vesting).
  • F7–F8: Vesting schedule details for option/warrant grants (1/4 on Apr 18, 2025, then monthly 1/48).
• Shares owned after the transactions are not specified in the provided excerpt of the filing.
• Filing date: Form 4 filed Sept 15, 2026. No late filing flag indicated in the provided data.

Context

• Exercise + sale on the same day can be a cashless or near‑term monetization of option value; here Goncalves paid ~$51K to exercise 7,000 options and reported roughly $734K in sale proceeds from open‑market transactions the same day.
• Sales conducted under a 10b5‑1 plan and some sales attributable to sell‑to‑cover for tax withholding are routine mechanisms and do not, by themselves, indicate personal views about the company’s prospects.
• Derivative transactions reported at $0.00 likely reflect internal net settlement or conversion details reported on the Form 4; see the filing footnotes for ranges and exact per‑trade prices and contact the company or SEC staff for full per‑trade breakdown if needed.